Claritev vs HealthEquity
CTEV and HQY side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTEV and HQY compare
HealthEquity is the larger company, worth 21 times as much as Claritev ($8.5B against $407M).
HealthEquity grew revenue faster over the last twelve months (7.3% versus 6.3% for Claritev).
HealthEquity keeps more of each dollar of sales as profit, with a net margin of 17.4% compared with −28.5% at Claritev.
HealthEquity scores higher on the StockData Score (15 against 3 for Claritev), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTEV | HQY |
|---|---|---|
| Size and price | ||
| Market cap | $407M | $8.5B |
| Share price | $24.00 | $102.47 |
| Change, 1 year | −65.0% | 8.5% |
| Change, 5 years | −84.8% | 50.2% |
| Beta (5Y) | 1.21 | 0.39 |
| Employees | 3,000 | 2,814 |
| StockData Score | ||
| Total score | 3 | 15 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 37.0× |
| P/S | 0.4× (better) | 6.2× |
| P/B | – | 4.3× |
| EV/EBITDA | 154× | 18.0× (better) |
| P/FCF | – | 17.4× |
| FCF yield | −4.4% | 5.8% (better) |
| Fair value | – | $109.86 |
| Margin of safety | – | 6.7% |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 7.3% (better) |
| Revenue growth, 5Y average | 0.58% | 12.4% (better) |
| Net income growth (TTM) | – | 62.2% |
| EPS growth (TTM) | – | 67.9% |
| EPS growth, 5Y average | – | 83.0% |
| Profitability | ||
| Gross margin | 73.0% (better) | 71.2% |
| Operating margin | 3.3% | 25.8% (better) |
| Net margin | −28.5% | 17.4% (better) |
| FCF margin | −1.8% | 35.8% (better) |
| Return on equity | – | 11.4% |
| Return on invested capital | 0.59% | 9.8% (better) |
| Financial health | ||
| Debt / equity | – | 0.47 |
| Net debt / EBITDA | 141.21 | 1.33 (better) |
| Interest coverage | 0.1× | 6.7× (better) |
| Current ratio | 1.00 | 2.99 (better) |
| Altman Z-score | −0.47 | 4.92 (better) |
| Piotroski F-score | 5 | 9 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.49% | 4.8% (better) |
| Shareholder yield | −0.49% | 4.8% (better) |
| Ownership | ||
| Held by institutions | 91.0% | 109% |
| Held by insiders | 50.2% | 1.7% |
| Insider net buying, 12 months | −$71.6M | −$4.2M (better) |
| Short interest, % of float | 11.6% | 7.4% |
Go deeper
- CTEV stock overview
- CTEV income statement
- CTEV valuation and score
- HQY stock overview
- HQY income statement
- HQY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.